The landscape of dementia prognosis has evolved radically with the advent of refined biomarkers, together with amyloid PET scans, tau imaging, and blood-based tests that will detect Alzheimer's pathology several years in advance of symptoms emerge. Whilst these technological developments symbolize impressive development in understanding neurodegene